![biaoTi](/_nuxt/img/biaoTi.0d1dc71.webp)
![biaoTi](/_nuxt/img/biaoTi.0d1dc71.webp)
Part 1
Part 2
Part 3
Part 5
Hip Osteoarthritis Pain Drug is to relieve pain, and cannot slow the progress of osteoarthritis. The global market for Hip Osteoarthritis Pain Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Report Scope This report aims to provide a comprehensive presentation of the global market for Hip Osteoarthritis Pain Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hip Osteoarthritis Pain Drug by region & country, by Type, and by Application. The Hip Osteoarthritis Pain Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hip Osteoarthritis Pain Drug. Market Segmentation
Report Metric
Details
Report Title
Hip Osteoarthritis Pain Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Hip Osteoarthritis Pain Drug Companies Covered
Pfizer, Johnson and Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma
Global Hip Osteoarthritis Pain Drug Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hip Osteoarthritis Pain Drug Market, Segment by Type
Oral
Injection
External
Global Hip Osteoarthritis Pain Drug Market, Segment by Application
Medical Care
Personal Care
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends
Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Hip Osteoarthritis Pain Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Sales, revenue of Hip Osteoarthritis Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Sales, revenue of Hip Osteoarthritis Pain Drug in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion.
1 Market Overview
1.1 Hip Osteoarthritis Pain Drug Product Introduction
1.2 Global Hip Osteoarthritis Pain Drug Market Size Forecast
1.2.1 Global Hip Osteoarthritis Pain Drug Sales Value (2019-2030)
1.2.2 Global Hip Osteoarthritis Pain Drug Sales Volume (2019-2030)
1.2.3 Global Hip Osteoarthritis Pain Drug Sales Price (2019-2030)
1.3 Hip Osteoarthritis Pain Drug Market Trends & Drivers
1.3.1 Hip Osteoarthritis Pain Drug Industry Trends
1.3.2 Hip Osteoarthritis Pain Drug Market Drivers & Opportunity
1.3.3 Hip Osteoarthritis Pain Drug Market Challenges
1.3.4 Hip Osteoarthritis Pain Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered2 Competitive Analysis by Company
2.1 Global Hip Osteoarthritis Pain Drug Players Revenue Ranking (2023)
2.2 Global Hip Osteoarthritis Pain Drug Revenue by Company (2019-2024)
2.3 Global Hip Osteoarthritis Pain Drug Players Sales Volume Ranking (2023)
2.4 Global Hip Osteoarthritis Pain Drug Sales Volume by Company Players (2019-2024)
2.5 Global Hip Osteoarthritis Pain Drug Average Price by Company (2019-2024)
2.6 Key Manufacturers Hip Osteoarthritis Pain Drug Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Hip Osteoarthritis Pain Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Hip Osteoarthritis Pain Drug
2.9 Hip Osteoarthritis Pain Drug Market Competitive Analysis
2.9.1 Hip Osteoarthritis Pain Drug Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Hip Osteoarthritis Pain Drug Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hip Osteoarthritis Pain Drug as of 2023)
2.10 Mergers & Acquisitions, Expansion3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral
3.1.2 Injection
3.1.3 External
3.2 Global Hip Osteoarthritis Pain Drug Sales Value by Type
3.2.1 Global Hip Osteoarthritis Pain Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Hip Osteoarthritis Pain Drug Sales Value, by Type (2019-2030)
3.2.3 Global Hip Osteoarthritis Pain Drug Sales Value, by Type (%) (2019-2030)
3.3 Global Hip Osteoarthritis Pain Drug Sales Volume by Type
3.3.1 Global Hip Osteoarthritis Pain Drug Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Hip Osteoarthritis Pain Drug Sales Volume, by Type (2019-2030)
3.3.3 Global Hip Osteoarthritis Pain Drug Sales Volume, by Type (%) (2019-2030)
3.4 Global Hip Osteoarthritis Pain Drug Average Price by Type (2019-2030)4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Medical Care
4.1.2 Personal Care
4.2 Global Hip Osteoarthritis Pain Drug Sales Value by Application
4.2.1 Global Hip Osteoarthritis Pain Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Hip Osteoarthritis Pain Drug Sales Value, by Application (2019-2030)
4.2.3 Global Hip Osteoarthritis Pain Drug Sales Value, by Application (%) (2019-2030)
4.3 Global Hip Osteoarthritis Pain Drug Sales Volume by Application
4.3.1 Global Hip Osteoarthritis Pain Drug Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Hip Osteoarthritis Pain Drug Sales Volume, by Application (2019-2030)
4.3.3 Global Hip Osteoarthritis Pain Drug Sales Volume, by Application (%) (2019-2030)
4.4 Global Hip Osteoarthritis Pain Drug Average Price by Application (2019-2030)5 Segmentation by Region
5.1 Global Hip Osteoarthritis Pain Drug Sales Value by Region
5.1.1 Global Hip Osteoarthritis Pain Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Hip Osteoarthritis Pain Drug Sales Value by Region (2019-2024)
5.1.3 Global Hip Osteoarthritis Pain Drug Sales Value by Region (2025-2030)
5.1.4 Global Hip Osteoarthritis Pain Drug Sales Value by Region (%), (2019-2030)
5.2 Global Hip Osteoarthritis Pain Drug Sales Volume by Region
5.2.1 Global Hip Osteoarthritis Pain Drug Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Hip Osteoarthritis Pain Drug Sales Volume by Region (2019-2024)
5.2.3 Global Hip Osteoarthritis Pain Drug Sales Volume by Region (2025-2030)
5.2.4 Global Hip Osteoarthritis Pain Drug Sales Volume by Region (%), (2019-2030)
5.3 Global Hip Osteoarthritis Pain Drug Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
5.4.2 North America Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
5.5.2 Europe Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
5.6.2 Asia Pacific Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
5.7.2 South America Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
5.8.2 Middle East & Africa Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 20306 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value
6.2.1 Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.2.2 Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.3.2 United States Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.4.2 Europe Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.5.2 China Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.6.2 Japan Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.7.2 South Korea Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Hip Osteoarthritis Pain Drug Sales Value, 2019-2030
6.9.2 India Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Hip Osteoarthritis Pain Drug Sales Value by Application, 2023 VS 20307 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Hip Osteoarthritis Pain Drug Product Offerings
7.1.5 Pfizer Recent Development
7.2 Johnson and Johnson
7.2.1 Johnson and Johnson Company Information
7.2.2 Johnson and Johnson Introduction and Business Overview
7.2.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Johnson and Johnson Hip Osteoarthritis Pain Drug Product Offerings
7.2.5 Johnson and Johnson Recent Development
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Company Information
7.3.2 GlaxoSmithKline Introduction and Business Overview
7.3.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.3.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Offerings
7.3.5 GlaxoSmithKline Recent Development
7.4 Bayer
7.4.1 Bayer Company Information
7.4.2 Bayer Introduction and Business Overview
7.4.3 Bayer Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Bayer Hip Osteoarthritis Pain Drug Product Offerings
7.4.5 Bayer Recent Development
7.5 Eli Lilly
7.5.1 Eli Lilly Company Information
7.5.2 Eli Lilly Introduction and Business Overview
7.5.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Eli Lilly Hip Osteoarthritis Pain Drug Product Offerings
7.5.5 Eli Lilly Recent Development
7.6 Novartis
7.6.1 Novartis Company Information
7.6.2 Novartis Introduction and Business Overview
7.6.3 Novartis Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis Hip Osteoarthritis Pain Drug Product Offerings
7.6.5 Novartis Recent Development
7.7 Sanofi
7.7.1 Sanofi Company Information
7.7.2 Sanofi Introduction and Business Overview
7.7.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Sanofi Hip Osteoarthritis Pain Drug Product Offerings
7.7.5 Sanofi Recent Development
7.8 Horizon Pharma
7.8.1 Horizon Pharma Company Information
7.8.2 Horizon Pharma Introduction and Business Overview
7.8.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Horizon Pharma Hip Osteoarthritis Pain Drug Product Offerings
7.8.5 Horizon Pharma Recent Development
7.9 Abbott
7.9.1 Abbott Company Information
7.9.2 Abbott Introduction and Business Overview
7.9.3 Abbott Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Abbott Hip Osteoarthritis Pain Drug Product Offerings
7.9.5 Abbott Recent Development
7.10 Mylan
7.10.1 Mylan Company Information
7.10.2 Mylan Introduction and Business Overview
7.10.3 Mylan Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Mylan Hip Osteoarthritis Pain Drug Product Offerings
7.10.5 Mylan Recent Development
7.11 Daiichi Sankyo
7.11.1 Daiichi Sankyo Company Information
7.11.2 Daiichi Sankyo Introduction and Business Overview
7.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Offerings
7.11.5 Daiichi Sankyo Recent Development
7.12 TEVA
7.12.1 TEVA Company Information
7.12.2 TEVA Introduction and Business Overview
7.12.3 TEVA Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.12.4 TEVA Hip Osteoarthritis Pain Drug Product Offerings
7.12.5 TEVA Recent Development
7.13 Almatica Pharma
7.13.1 Almatica Pharma Company Information
7.13.2 Almatica Pharma Introduction and Business Overview
7.13.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Almatica Pharma Hip Osteoarthritis Pain Drug Product Offerings
7.13.5 Almatica Pharma Recent Development
7.14 Astellas Pharma
7.14.1 Astellas Pharma Company Information
7.14.2 Astellas Pharma Introduction and Business Overview
7.14.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Astellas Pharma Hip Osteoarthritis Pain Drug Product Offerings
7.14.5 Astellas Pharma Recent Development
7.15 Tide Pharmaceutical
7.15.1 Tide Pharmaceutical Company Information
7.15.2 Tide Pharmaceutical Introduction and Business Overview
7.15.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Offerings
7.15.5 Tide Pharmaceutical Recent Development
7.16 Iroko Pharmaceuticals
7.16.1 Iroko Pharmaceuticals Company Information
7.16.2 Iroko Pharmaceuticals Introduction and Business Overview
7.16.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Offerings
7.16.5 Iroko Pharmaceuticals Recent Development
7.17 Hengrui Pharmaceutical
7.17.1 Hengrui Pharmaceutical Company Information
7.17.2 Hengrui Pharmaceutical Introduction and Business Overview
7.17.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Offerings
7.17.5 Hengrui Pharmaceutical Recent Development
7.18 Abiogen Pharma
7.18.1 Abiogen Pharma Company Information
7.18.2 Abiogen Pharma Introduction and Business Overview
7.18.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Abiogen Pharma Hip Osteoarthritis Pain Drug Product Offerings
7.18.5 Abiogen Pharma Recent Development8 Industry Chain Analysis
8.1 Hip Osteoarthritis Pain Drug Industrial Chain
8.2 Hip Osteoarthritis Pain Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hip Osteoarthritis Pain Drug Sales Model
8.5.2 Sales Channel
8.5.3 Hip Osteoarthritis Pain Drug Distributors9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables Table 1. Hip Osteoarthritis Pain Drug Market Trends Table 2. Hip Osteoarthritis Pain Drug Market Drivers & Opportunity Table 3. Hip Osteoarthritis Pain Drug Market Challenges Table 4. Hip Osteoarthritis Pain Drug Market Restraints Table 5. Global Hip Osteoarthritis Pain Drug Revenue by Company (2019-2024) & (US$ Million) Table 6. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Company (2019-2024) Table 7. Global Hip Osteoarthritis Pain Drug Sales Volume by Company (2019-2024) & (K Units) Table 8. Global Hip Osteoarthritis Pain Drug Sales Volume Market Share by Company (2019-2024) Table 9. Global Market Hip Osteoarthritis Pain Drug Price by Company (2019-2024) & (USD/Unit) Table 10. Key Manufacturers Hip Osteoarthritis Pain Drug Manufacturing Base Distribution and Headquarters Table 11. Key Manufacturers Hip Osteoarthritis Pain Drug Product Type Table 12. Key Manufacturers Time to Begin Mass Production of Hip Osteoarthritis Pain Drug Table 13. Global Hip Osteoarthritis Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hip Osteoarthritis Pain Drug as of 2023) Table 15. Mergers & Acquisitions, Expansion Plans Table 16. Global Hip Osteoarthritis Pain Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million) Table 17. Global Hip Osteoarthritis Pain Drug Sales Value by Type (2019-2024) & (US$ Million) Table 18. Global Hip Osteoarthritis Pain Drug Sales Value by Type (2025-2030) & (US$ Million) Table 19. Global Hip Osteoarthritis Pain Drug Sales Market Share in Value by Type (2019-2024) & (%) Table 20. Global Hip Osteoarthritis Pain Drug Sales Market Share in Value by Type (2025-2030) & (%) Table 21. Global Hip Osteoarthritis Pain Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units) Table 22. Global Hip Osteoarthritis Pain Drug Sales Volume by Type (2019-2024) & (K Units) Table 23. Global Hip Osteoarthritis Pain Drug Sales Volume by Type (2025-2030) & (K Units) Table 24. Global Hip Osteoarthritis Pain Drug Sales Market Share in Volume by Type (2019-2024) & (%) Table 25. Global Hip Osteoarthritis Pain Drug Sales Market Share in Volume by Type (2025-2030) & (%) Table 26. Global Hip Osteoarthritis Pain Drug Price by Type (2019-2024) & (USD/Unit) Table 27. Global Hip Osteoarthritis Pain Drug Price by Type (2025-2030) & (USD/Unit) Table 28. Global Hip Osteoarthritis Pain Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million) Table 29. Global Hip Osteoarthritis Pain Drug Sales Value by Application (2019-2024) & (US$ Million) Table 30. Global Hip Osteoarthritis Pain Drug Sales Value by Application (2025-2030) & (US$ Million) Table 31. Global Hip Osteoarthritis Pain Drug Sales Market Share in Value by Application (2019-2024) & (%) Table 32. Global Hip Osteoarthritis Pain Drug Sales Market Share in Value by Application (2025-2030) & (%) Table 33. Global Hip Osteoarthritis Pain Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units) Table 34. Global Hip Osteoarthritis Pain Drug Sales Volume by Application (2019-2024) & (K Units) Table 35. Global Hip Osteoarthritis Pain Drug Sales Volume by Application (2025-2030) & (K Units) Table 36. Global Hip Osteoarthritis Pain Drug Sales Market Share in Volume by Application (2019-2024) & (%) Table 37. Global Hip Osteoarthritis Pain Drug Sales Market Share in Volume by Application (2025-2030) & (%) Table 38. Global Hip Osteoarthritis Pain Drug Price by Application (2019-2024) & (USD/Unit) Table 39. Global Hip Osteoarthritis Pain Drug Price by Application (2025-2030) & (USD/Unit) Table 40. Global Hip Osteoarthritis Pain Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 41. Global Hip Osteoarthritis Pain Drug Sales Value by Region (2019-2024) & (US$ Million) Table 42. Global Hip Osteoarthritis Pain Drug Sales Value by Region (2025-2030) & (US$ Million) Table 43. Global Hip Osteoarthritis Pain Drug Sales Value by Region (2019-2024) & (%) Table 44. Global Hip Osteoarthritis Pain Drug Sales Value by Region (2025-2030) & (%) Table 45. Global Hip Osteoarthritis Pain Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030 Table 46. Global Hip Osteoarthritis Pain Drug Sales Volume by Region (2019-2024) & (K Units) Table 47. Global Hip Osteoarthritis Pain Drug Sales Volume by Region (2025-2030) & (K Units) Table 48. Global Hip Osteoarthritis Pain Drug Sales Volume by Region (2019-2024) & (%) Table 49. Global Hip Osteoarthritis Pain Drug Sales Volume by Region (2025-2030) & (%) Table 50. Global Hip Osteoarthritis Pain Drug Average Price by Region (2019-2024) & (USD/Unit) Table 51. Global Hip Osteoarthritis Pain Drug Average Price by Region (2025-2030) & (USD/Unit) Table 52. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030 Table 53. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value, (2019-2024) & (US$ Million) Table 54. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value, (2025-2030) & (US$ Million) Table 55. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Volume, (2019-2024) & (K Units) Table 56. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Volume, (2025-2030) & (K Units) Table 57. Pfizer Company Information Table 58. Pfizer Introduction and Business Overview Table 59. Pfizer Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 60. Pfizer Hip Osteoarthritis Pain Drug Product Offerings Table 61. Pfizer Recent Development Table 62. Johnson and Johnson Company Information Table 63. Johnson and Johnson Introduction and Business Overview Table 64. Johnson and Johnson Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 65. Johnson and Johnson Hip Osteoarthritis Pain Drug Product Offerings Table 66. Johnson and Johnson Recent Development Table 67. GlaxoSmithKline Company Information Table 68. GlaxoSmithKline Introduction and Business Overview Table 69. GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 70. GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Offerings Table 71. GlaxoSmithKline Recent Development Table 72. Bayer Company Information Table 73. Bayer Introduction and Business Overview Table 74. Bayer Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 75. Bayer Hip Osteoarthritis Pain Drug Product Offerings Table 76. Bayer Recent Development Table 77. Eli Lilly Company Information Table 78. Eli Lilly Introduction and Business Overview Table 79. Eli Lilly Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 80. Eli Lilly Hip Osteoarthritis Pain Drug Product Offerings Table 81. Eli Lilly Recent Development Table 82. Novartis Company Information Table 83. Novartis Introduction and Business Overview Table 84. Novartis Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 85. Novartis Hip Osteoarthritis Pain Drug Product Offerings Table 86. Novartis Recent Development Table 87. Sanofi Company Information Table 88. Sanofi Introduction and Business Overview Table 89. Sanofi Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 90. Sanofi Hip Osteoarthritis Pain Drug Product Offerings Table 91. Sanofi Recent Development Table 92. Horizon Pharma Company Information Table 93. Horizon Pharma Introduction and Business Overview Table 94. Horizon Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 95. Horizon Pharma Hip Osteoarthritis Pain Drug Product Offerings Table 96. Horizon Pharma Recent Development Table 97. Abbott Company Information Table 98. Abbott Introduction and Business Overview Table 99. Abbott Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 100. Abbott Hip Osteoarthritis Pain Drug Product Offerings Table 101. Abbott Recent Development Table 102. Mylan Company Information Table 103. Mylan Introduction and Business Overview Table 104. Mylan Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 105. Mylan Hip Osteoarthritis Pain Drug Product Offerings Table 106. Mylan Recent Development Table 107. Daiichi Sankyo Company Information Table 108. Daiichi Sankyo Introduction and Business Overview Table 109. Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 110. Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Offerings Table 111. Daiichi Sankyo Recent Development Table 112. TEVA Company Information Table 113. TEVA Introduction and Business Overview Table 114. TEVA Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 115. TEVA Hip Osteoarthritis Pain Drug Product Offerings Table 116. TEVA Recent Development Table 117. Almatica Pharma Company Information Table 118. Almatica Pharma Introduction and Business Overview Table 119. Almatica Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 120. Almatica Pharma Hip Osteoarthritis Pain Drug Product Offerings Table 121. Almatica Pharma Recent Development Table 122. Astellas Pharma Company Information Table 123. Astellas Pharma Introduction and Business Overview Table 124. Astellas Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 125. Astellas Pharma Hip Osteoarthritis Pain Drug Product Offerings Table 126. Astellas Pharma Recent Development Table 127. Tide Pharmaceutical Company Information Table 128. Tide Pharmaceutical Introduction and Business Overview Table 129. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 130. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Offerings Table 131. Tide Pharmaceutical Recent Development Table 132. Iroko Pharmaceuticals Company Information Table 133. Iroko Pharmaceuticals Introduction and Business Overview Table 134. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 135. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Offerings Table 136. Iroko Pharmaceuticals Recent Development Table 137. Hengrui Pharmaceutical Company Information Table 138. Hengrui Pharmaceutical Introduction and Business Overview Table 139. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 140. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Offerings Table 141. Hengrui Pharmaceutical Recent Development Table 142. Abiogen Pharma Company Information Table 143. Abiogen Pharma Introduction and Business Overview Table 144. Abiogen Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 145. Abiogen Pharma Hip Osteoarthritis Pain Drug Product Offerings Table 146. Abiogen Pharma Recent Development Table 147. Key Raw Materials Lists Table 148. Raw Materials Key Suppliers Lists Table 149. Hip Osteoarthritis Pain Drug Downstream Customers Table 150. Hip Osteoarthritis Pain Drug Distributors List Table 151. Research Programs/Design for This Report Table 152. Key Data Information from Secondary Sources Table 153. Key Data Information from Primary Sources List of Figures Figure 1. Hip Osteoarthritis Pain Drug Product Picture Figure 2. Global Hip Osteoarthritis Pain Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Hip Osteoarthritis Pain Drug Sales Value (2019-2030) & (US$ Million) Figure 4. Global Hip Osteoarthritis Pain Drug Sales Volume (2019-2030) & (K Units) Figure 5. Global Hip Osteoarthritis Pain Drug Sales Price (2019-2030) & (USD/Unit) Figure 6. Hip Osteoarthritis Pain Drug Report Years Considered Figure 7. Global Hip Osteoarthritis Pain Drug Players Revenue Ranking (2023) & (US$ Million) Figure 8. Global Hip Osteoarthritis Pain Drug Players Sales Volume Ranking (2023) & (K Units) Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Hip Osteoarthritis Pain Drug Revenue in 2023 Figure 10. Hip Osteoarthritis Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 11. Oral Picture Figure 12. Injection Picture Figure 13. External Picture Figure 14. Global Hip Osteoarthritis Pain Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million) Figure 15. Global Hip Osteoarthritis Pain Drug Sales Value Market Share by Type, 2023 & 2030 Figure 16. Global Hip Osteoarthritis Pain Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units) Figure 17. Global Hip Osteoarthritis Pain Drug Sales Volume Market Share by Type, 2023 & 2030 Figure 18. Global Hip Osteoarthritis Pain Drug Price by Type (2019-2030) & (USD/Unit) Figure 19. Product Picture of Medical Care Figure 20. Product Picture of Personal Care Figure 21. Global Hip Osteoarthritis Pain Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million) Figure 22. Global Hip Osteoarthritis Pain Drug Sales Value Market Share by Application, 2023 & 2030 Figure 23. Global Hip Osteoarthritis Pain Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units) Figure 24. Global Hip Osteoarthritis Pain Drug Sales Volume Market Share by Application, 2023 & 2030 Figure 25. Global Hip Osteoarthritis Pain Drug Price by Application (2019-2030) & (USD/Unit) Figure 26. North America Hip Osteoarthritis Pain Drug Sales Value (2019-2030) & (US$ Million) Figure 27. North America Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030 Figure 28. Europe Hip Osteoarthritis Pain Drug Sales Value (2019-2030) & (US$ Million) Figure 29. Europe Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030 Figure 30. Asia Pacific Hip Osteoarthritis Pain Drug Sales Value (2019-2030) & (US$ Million) Figure 31. Asia Pacific Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030 Figure 32. South America Hip Osteoarthritis Pain Drug Sales Value (2019-2030) & (US$ Million) Figure 33. South America Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030 Figure 34. Middle East & Africa Hip Osteoarthritis Pain Drug Sales Value (2019-2030) & (US$ Million) Figure 35. Middle East & Africa Hip Osteoarthritis Pain Drug Sales Value by Country (%), 2023 VS 2030 Figure 36. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Value (%), (2019-2030) Figure 37. Key Countries/Regions Hip Osteoarthritis Pain Drug Sales Volume (%), (2019-2030) Figure 38. United States Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 39. United States Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 40. United States Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 41. Europe Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 42. Europe Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 43. Europe Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 44. China Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 45. China Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 46. China Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 47. Japan Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 48. Japan Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 49. Japan Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 50. South Korea Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 51. South Korea Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 52. South Korea Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 53. Southeast Asia Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 54. Southeast Asia Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 55. Southeast Asia Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 56. India Hip Osteoarthritis Pain Drug Sales Value, (2019-2030) & (US$ Million) Figure 57. India Hip Osteoarthritis Pain Drug Sales Value by Type (%), 2023 VS 2030 Figure 58. India Hip Osteoarthritis Pain Drug Sales Value by Application (%), 2023 VS 2030 Figure 59. Hip Osteoarthritis Pain Drug Industrial Chain Figure 60. Hip Osteoarthritis Pain Drug Manufacturing Cost Structure Figure 61. Channels of Distribution (Direct Sales, and Distribution) Figure 62. Bottom-up and Top-down Approaches for This Report Figure 63. Data Triangulation Figure 64. Key Executives Interviewed
Hip Osteoarthritis Pain Drug is to relieve pain, and cannot slow the progress of osteoarthritis. The global market for Hip Osteoarthritis Pain Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Report Scope This report aims to provide a comprehensive presentation of the global market for Hip Osteoarthritis Pain Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hip Osteoarthritis Pain Drug by region & country, by Type, and by Application. The Hip Osteoarthritis Pain Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hip Osteoarthritis Pain Drug. Market Segmentation
Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Hip Osteoarthritis Pain Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Sales, revenue of Hip Osteoarthritis Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Sales, revenue of Hip Osteoarthritis Pain Drug in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion.
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
English
Simon Lee
English
Hitesh
Chinese
Damon
Japanese
Tang Xin
Korean
Sung-Bin Yoon
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
Fastest report delivery service
More than 17 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
English
Simon Lee
English
Hitesh
Chinese
Damon
Japanese
Tang Xin
Korean
Sung-Bin Yoon
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
Fastest report delivery service
More than 17 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
Add to Cart
Buy Now